Clinical-stage biotechnology company REGENXBIO Inc (Nasdaq: RGNX) on Wednesday reported revenue of USD62.1m for nine months ended 30 September 2024, compared to USD68.0m for the same period a year ago.

Net loss for the nine-month period was USD175.9m or USD3.59 basic and diluted net loss per share, compared to USD200.6m or USD4.60 basic and diluted net loss per share for the same period in 2023.

"It has been a turning point year for REGENXBIO, as we are on the cusp of advancing AFFINITY DUCHENNE to pivotal phase, completing our first BLA for MPS II and entering pivotal phase in a second indication within our global eyecare collaboration with AbbVie," commented Curran M. Simpson, president and CEO of REGENXBIO.

"The rapid progress we are making in RGX-202, which continues to demonstrate its potential to be a best-in-class gene therapy for Duchenne, is highly encouraging, and the near-term filing of our BLA for RGX-121 represents a major milestone for the patient community in need of a treatment to address both the neurocognitive and systemic effects of MPS II. The recent fellow eye data presented at the American Academy of Ophthalmology meeting demonstrate the potential of ABBV-RGX-314 to preserve vision long-term for patients with wet AMD as a one-time treatment for both eyes.

"Each of these programs represent one-time treatments with the potential to transform the trajectory and management of disease for patients in need of new and better options, and we look forward to continued momentum and important milestones in the last quarter of the year."